Market Size of North America Glucagon-like Peptide-1 Agonists Industry
| Study Period | 2018 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 6.94 Billion |
| Market Size (2029) | USD 6.68 Billion |
| CAGR (2024 - 2029) | -0.76 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
North America GLP-1 Agonists Market Analysis
The North America Glucagon-like Peptide-1 Agonists Market size is estimated at USD 6.94 billion in 2024, and is expected to decline to USD 6.68 billion by 2029.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of medications used for the treatment of type 2 diabetes and some drugs are also approved for obesity. One of the benefits of this class of drugs over sulfonylureas or meglitinides is that they have a lower risk of causing hypoglycemia. Besides being important glucose-lowering agents, GLP-1RAs have significant anti-inflammatory and pulmonary protective effects and an advantageous impact on gut microbes' composition.
The North American region had witnessed an alarming increase in the prevalence of diabetes, in recent years. In developed countries, such as the United States and Canada, the rate of diabetes is at an all-time high, mainly due to lifestyle changes. Diabetes is associated with many health complications. Patients with diabetes require many corrections throughout the day for maintaining nominal blood glucose levels, such as the administration of additional insulin or ingestion of additional carbohydrates by monitoring their blood glucose levels.
The Centers for Disease Control and Prevention National Diabetes Statistics Report 2022 estimated that more than 130 million adults are living with diabetes or prediabetes in the United States. Type 2 diabetes is more common, and diabetes is more consequential among communities of color, those who live in rural areas, and those with less education, lower incomes, and lower health literacy.
Owing to the rising prevalence and factors above, the growth of the studied market is anticipated over the forecast period.
North America GLP-1 Agonists Industry Segmentation
GLP-1 receptor agonists are a non-insulin medication combined with diet and exercise to help treat type 2 diabetes. The North American Glucagon-like Peptide-1 (GLP-1) Agonists Market is segmented into drugs and geography. The report offers the value (in USD) and volume (in units) for the above segments.
| Drugs | ||||
| ||||
| ||||
| ||||
| ||||
|
| Geography | |
| United States | |
| Canada | |
| Rest of North America |
North America Glucagon-like Peptide-1 Agonists Market Size Summary
The North America Glucagon-like Peptide-1 Agonists Market is poised for growth, driven by the increasing prevalence of type 2 diabetes and obesity in the region. GLP-1 receptor agonists are a crucial class of medications that not only help in managing blood glucose levels but also offer benefits such as reduced risk of hypoglycemia, anti-inflammatory effects, and positive impacts on gut microbiota. These medications are particularly important in the United States and Canada, where lifestyle changes have led to a surge in diabetes cases. The market is characterized by the presence of major pharmaceutical companies like Eli Lilly, Sanofi, Novo Nordisk, and AstraZeneca, which are actively involved in the development and distribution of these therapies. The approval of new drugs and combination therapies, such as semaglutide and tirzepatide, further underscores the dynamic nature of this market.
Despite the anticipated growth, the market faces challenges, including competition from more effective alternatives like exenatide and semaglutide, which may impact the sales of existing products such as Liraglutide. The market's consolidation with key players and the introduction of cost-saving programs, like the Victoza Instant Savings Card, aim to make these therapies more accessible. The United States holds a significant share of the market, reflecting the high demand for effective diabetes and obesity treatments. Regulatory approvals, such as those from the U.S. Food and Drug Administration for pediatric obesity treatments, highlight the ongoing innovation and expansion within the market. Overall, the North America GLP-1 Agonists Market is expected to experience a complex interplay of growth opportunities and competitive pressures over the forecast period.
North America Glucagon-like Peptide-1 Agonists Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.3 Market Restraints
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Bargaining Power of Suppliers
-
1.4.2 Bargaining Power of Consumers
-
1.4.3 Threat of New Entrants
-
1.4.4 Threat of Substitute Products and Services
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. Market Segmentation
-
2.1 Drugs
-
2.1.1 Dulaglutide
-
2.1.1.1 Trulicity
-
-
2.1.2 Exenatide
-
2.1.2.1 Byetta
-
2.1.2.2 Bydureon
-
-
2.1.3 Liraglutide
-
2.1.3.1 Victoza
-
-
2.1.4 Lixisenatide
-
2.1.4.1 Lyxumia
-
-
2.1.5 Semaglutide
-
2.1.5.1 Ozempic
-
-
-
2.2 Geography
-
2.2.1 United States
-
2.2.2 Canada
-
2.2.3 Rest of North America
-
-
North America Glucagon-like Peptide-1 Agonists Market Size FAQs
What is the current North America Glucagon-like Peptide-1 Agonists Market size?
In 2024, the North America Glucagon-like Peptide-1 Agonists Market size is expected to reach USD 6.94 billion.
Who are the key players in North America Glucagon-like Peptide-1 Agonists Market?
Astrazeneca, Sanofi, Eli Lilly and Company, Pfizer Inc. and Novo Nordisk A/S are the major companies operating in the North America Glucagon-like Peptide-1 Agonists Market.
